We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




New QC Reagents Compatible with Multiple Immunoassay Platforms

By LabMedica International staff writers
Posted on 22 Sep 2019
Print article
Image: The new Acusera quality control reagents are designed for cost-effectiveness, as well as accurate and reproducible results (Photo courtesy of Randox).
Image: The new Acusera quality control reagents are designed for cost-effectiveness, as well as accurate and reproducible results (Photo courtesy of Randox).
A new set of infectious disease (serology) quality control reagents is designed to deliver a cost-effective, high-quality solution for the analysis of infectious diseases, while producing repeatable trustworthy results on various immunoassay platforms.

The Randox (Crumlin, United Kingdom) Quality Control Acusera Infectious Disease Serology Controls cover a wide range of infectious diseases, including HIV, hepatitis, EBV, CMV, Varicella zoster virus, ToRCH, Lyme disease and others. These controls are compatible for use on some of the most popular immunoassay platforms including Roche, Abbott, Siemens and Beckman among others.

The Acusera control reagents are manufactured from human plasma, and each control is designed to react to the test system in the same manner as the patient sample. The new controls meet ISO 15189:2012 requirements and reduce inconvenient shifts in QC results when reagent batches are changed.

The reagents, which have been optimized for use by microbiology and virology laboratories, blood banks, public health laboratories, and clinical laboratories performing serology testing, have working stability of 60 days.

Lynsey Adams, Quality Control Manager at Randox, said, “These controls are the first of their kind on the market to be used on a wide range of immunoassay analyzers. Unlike the current practice of analyzer-specific tests, these controls can be used across a wide range of laboratory technologies and, with a working stability of 60 days at two to eight degrees Celsius, waste and costs are kept to a minimum.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.